Corporate Banner
Satellite Banner
Mass Spectrometry
Scientific Community
Become a Member | Sign in
Home>News>This Article

Bruker Announces Powerful New Mass Spectrometry Systems and Solutions

Published: Tuesday, June 11, 2013
Last Updated: Tuesday, June 11, 2013
Bookmark and Share
Company announces mass spectrometry-based product introductions for life-science research, clinical research, pharma and applied markets.

At the 61st ASMS Conference on Mass Spectrometry and Allied Topics, Bruker has announced mass spectrometry-based product introductions for life-science and clinical research, for biotech/pharma/CRO customers, as well as for industrial and applied markets.

The new mass spectrometry systems and solutions are designed to deliver confident analyses with dramatically enhanced resolution, sensitivity and precision.

The analytical utility of extreme performance will be presented in Bruker's users' symposium, breakfast workshops, and hospitality suite with emphasis on the following market/applications areas: systems biology, proteomics and metabolomics; biologics & pharmaceuticals; MALDI molecular imaging for pathology research and drug development; petroleomics, energy and industrial applications; applied markets including food, forensics and environmental analysis; as well as MALDI Biotyper-based clinical microbiology.

New Bruker products introduced at ASMS 2013 include:

SolariX™ XR:
With the scientifically acclaimed ParaCell™ as its core technology, the solariX XR FTMS (Fourier Transform Mass Spectrometry) system is redefining the way researchers approach chemical analysis by utilizing the concept of eXtreme Resolution throughout a wide variety of analytical workflows.

Combining the ParaCell with advanced processing technology enables the solariX XR to provide resolving powers of greater than 650,000 in a 1 second acquisition (at m/z 400) for routine LC/MS or MALDI imaging experiments, and ultimately over 10 million resolving power for the most challenging complex mixture applications, from top-down proteomics, to petroleomics and dissolved-organic matter (DOM) analysis, to eXtreme Resolution MALDI imaging.

This is a powerful advance in the mass spectrometry and provides access to previously hidden insights, and to chemical information never accessible before with mass spectrometry.

For the first time, chemists can 'read' the specific molecular formula for detected compounds from the eXtreme Resolution mass spectrum - essentially with certainty. This concept is especially relevant for metabolomics or workflows where information about the chemical genesis of a compound is not known, quantities available are not sufficient for other analytical methods, and all high-sensitivity information must be determined from mass spectral data alone.

Dr. Charles Cheng of Pfizer's Development Analytical division commented: "The isotopic fine structure that is easily revealed by the extreme resolution of the new solariX XR is of tremendous value for structural elucidation on unknowns. This fundamentally new ability to gain complete confidence in assignment of elemental formula perfectly complements our internal NMR activities at Pfizer. MALDI -FTMS was also surprisingly useful for small molecule analysis, enabling rapid high-throughput screening for statistically based impurity analysis at extreme resolution."

This novel eXtreme resolution platform is made easily applicable to a wide variety of applications by leveraging the Bruker portfolio of industry-leading MS analysis software solutions and ionization sources, such as CaptiveSpray for robust, high-sensitivity capillary and nano-flow applications.

The solariX XR features an advanced dual-source ion funnel which allows effortless (~5s) changeover from API (ESI or APCI) to MALDI, thus enabling workflows such as MALDI imaging, automation for high-throughput screening (96-384 well targets) and top-down MALDI sequencing to supplement ETD and ECD sequencing of large biomolecules.

The robust ion optics design of solariX XR combined with intuitive FTMS Control software results in a user interface that allows effortless, record-breaking performance. Advanced processing and mining of information-rich data sets is performed automatically and on-the-fly using Bruker applications platforms including: new flex Imaging 4.0 for MALDI imaging, Profile Analysis for statistical treatment of complex data sets, and Data Analysis with Smart Formula XR for automated interpretation of isotopic fine structure for exact elemental formula determination.

Impact™ HD and CaptiveSpray™ NanoBooster™ Source:
The new Impact HD is the latest innovation in Bruker's unique UHR-QqTOF (Ultra-High Resolution Qq-Time-Of-Flight) mass spectrometry product line with industry-leading >40,000 Full-Sensitivity Resolution (FSR). It opens up enhanced analytical performance levels for all applications where trace analysis from complex, high-background matrices is a challenge - such as biomarker research, identification of impurities or residue screening.

Thanks to its extreme sensitivity, broad mass-transfer ion optics and the fastest 50 Gbit/sec sampling technology, a dynamic range of 5 orders of magnitude is achieved at UHPLC speeds, with up to 50 Hz MS/MS capabilities. This is a prerequisite for high-resolution, accurate mass detection of low abundance compounds in nano- and UHPLC peaks.

Moreover, the Impact HD comes equipped with unique Instant Expertise™ software: intelligent self-optimizing MS/MS acquisition establishes optimal experimental conditions that are independent of sample amount or complexity. This translates into higher productivity and expert-caliber results - the first time!

In combination with the impact HD, Bruker also introduces the novel CaptiveSpray nanoBooster™ for new performance levels in proteomics and glycoanalysis. This newest version of Bruker's highly regarded CaptiveSpray ion source with proprietary dopant-enriched ionization boosts nano-flow sensitivity, and drives up protein and peptide ID rates significantly.

The emphasis of higher charge states and its sensitivity gain also provide highest ETD sensitivity with Bruker's amaZon ETD ion trap mass spectrometer, and allow for the analysis of low-level glycopeptides that were previously not measurable.

"Highest dynamic range really is compelling for proteomics analysis when it can genuinely be delivered at UHPLC speeds," commented Dr. Carsten Bässmann, Bruker's Head of ESI Applications Development. "At ASMS 2013, we can for this first time show the unique identification of more than 8,440 proteins at a low false discovery rate (FDR) below 1%, in a proteomics sample, using an integrated workflow combining 2D-LC separations with a CaptiveSpray nanoBooster™ source on our new impact HD system."

EVOQ™ Elite ER:
The new EVOQ Elite ER highlights the premiere of LC/MS/MS triple-quadrupole (TQ) technology from Bruker at ASMS. The new EVOQ Elite ER is the latest addition to the EVOQ family of LC-TQ systems, with an extended mass range to 2,000 m/z, for peptide quantitation or other high m/z applications.

The EVOQ LC-TQ platform features major innovations:
• the industry's first Vacuum-Insulated Probe (VIP™) heated electrospray ionization (HESI) source preserves and ionizes thermally fragile molecules without discrimination and with outstanding sensitivity
• the Active Exhaust atmospheric pressure ionization source with a robust orifice vacuum interface significantly enhances quantitative robustness for difficult samples
• flat-tuning, proprietary Interlaced Quadrupole Dual Funnel (IQ-DF™) maximizes sensitivity
• Bruker's patented lens-free triple-quad mass filter design enhances MRM ease and performance
• novel PACER™ software enables exception-based data-review, a revolutionary feature that significantly reduces the error rate for quantitative analysis;

All EVOQ LC-TQ systems incorporate Bruker's new Advance™ Ultra-High Pressure Liquid Chromatography (UHPLC) systems. The Advance HPLC, UHPLC, and the UHPLC-OLE (on-line extraction) products offer ultra-low dead volume, which enables excellent reproducibility at analytical flow-rates, an integrated column-oven, and bench-space savings.

Paired with the industry-leading CTC auto-sampler, the EVOQ LC-TQ delivers the precision and accuracy required for sustained, high-sensitivity LC-MRM quantitative analysis.

Rohan Thakur, Ph.D., Vice President and General Manager of Bruker's Quadrupole MS Business, stated: "The debut of the EVOQ LC-TQ at ASMS marks the first time that Bruker has brought LC triple quad technology to the premiere meeting for mass spectrometry. The key innovations in the EVOQ systems are designed to erase the pain points in today's high volume applied markets laboratories. Laboratories supporting food testing (pesticide residues or adulterants), environmental labs (industrial pollutants or personal care products), or toxicology (drug testing/doping, pain management) will benefit from the superior performance of the EVOQ family. Bruker's commitment to driving Innovation with Integrity is not just a tagline, it is our core philosophy."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,700+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

PREMIER Biosoft Announces Reseller Agreement with Bruker
Agreement aims to advance lipidomics and metabolomics research.
Monday, November 17, 2014
Bruker Sells GC Business
Bruker completed the divestiture of its GC and GC single-quadrupole (GC-SQ) mass spectrometry products to Techcomp Europe Ltd on October 31st.
Tuesday, November 04, 2014
Using LC-MS to Analyse Sulfonamides in Food Grade Honey
Sulfonamides are one of a number of groups of chemicals whose presence in honey is limited by international regulations.
Tuesday, July 22, 2014
Bruker MALDI Biotyper™ Receives CFDA Clearance
Company receives clearance from the China Food and Drug Administration to market and sell its IVD MALDI Biotyper System as a medical device in China for the identification of microorganisms isolated from human specimens.
Thursday, June 26, 2014
Bruker Reports 7% Revenue Growth in Q4
Bruker Corporation reported financial results for its fourth quarter and full year ended December 31, 2013.
Wednesday, February 19, 2014
Bruker Granted FDA Clearance to Market the MALDI Biotyper CA System
Bruker able to market MALDI Biotyper CA System in the US for the identification of Gram negative bacterial colonies cultured from human specimens.
Tuesday, November 26, 2013
Bruker and SISCAPA Assay Technologies Announce Second-Phase Collaboration Agreement
The ongoing collaboration aims to exploit MALDI-TOF instruments as an alternative to nano-LC-MS technology currently used in many SISCAPA assays.
Monday, September 16, 2013
Bruker and ImaBiotech Announces Collaboration
Bruker to distribute ImaBiotech's Quantinetix software for quantitative MALDI imaging.
Friday, June 21, 2013
Bruker and 3M Sign Exclusive Patent License Agreement
The licensed 3M patents are directed to a technique for performing mass spectrometry analysis on proteins in tissue that has been preserved in paraffin.
Tuesday, June 04, 2013
Bruker and SCiLS GmbH Announce an Exclusive Partnership
SCiLS Lab is the software developed by SCiLS GmbH which allows the user-friendly statistical analysis of large MALDI imaging datasets.
Wednesday, May 15, 2013
Biodesix Announces Agreement with Bruker Daltonics
The collaborative agreement sees Bruker Daltonics support Biodesix’ VeriStrat diagnostic test as well as future diagnostic tests based on MALDI-TOF mass spectrometry.
Wednesday, April 24, 2013
Bruker and the Genome British Columbia Proteomics Centre to Collaborate
The collaborative effort covers the development and validation of high-throughput assays for determining hemoglobin variants and diabetes risk.
Thursday, April 18, 2013
Bruker and Erasmus Medical Center Sign an Exclusive Licensing Agreement
Agreement for adding rapid beta-lactamase testing capabilities to the MALDI Biotyper system.
Friday, January 04, 2013
Bruker Announces New UK Centre of Excellence
Company introduces its integrated, state-of-the-art demonstration, applications and customer collaboration facilities.
Wednesday, October 03, 2012
Bruker and JMI Laboratories Announce Collaboration for Mass Spectrometry
The collaboration sees Bruker and JMI Laboratories partner in the field of fungal identification by proteomics fingerprinting.
Wednesday, June 20, 2012
Scientific News
Education and Expense: The Barriers to Mass Spectrometry in Clinical Laboratories?
Here we examine the perceived barriers to mass spec in clinical laboratories and explore the possible drivers behind the recent shift in uptake of the technology in clinical settings.
Metabolomic Platform Reveals Fundamental Flaw in Common Lab Technology
A new study led by scientists at The Scripps Research Institute (TSRI) shows that a technology used in thousands of laboratories, called gas chromatography mass spectrometry (GC-MS), fundamentally alters the samples it analyzes.
New Hope for Personalized Treatment of Eczema
Pharmaceutical researchers at Oregon State University have developed a new approach to treat eczema and other inflammatory skin disorders that would use individual tests and advanced science to create personalized treatments based on each person's lipid deficiencies.
Flowing Electrons Help Ocean Microbes Gulp Methane
Recent work at Caltech has shown that microbes work together to consume large amounts of methane released from vents on the ocean floor by using electrons to share energy over long distances.
Thousands of Protein Interactions Identified
Thanks to the work by Utrecht University researcher Fan Liu and her colleagues, it is now possible to map the interactions between proteins in human cells.
Newly Identified Biochemical Pathway Could Be Target for Insulin Control
Researchers at Duke Medicine and the University of Alberta are reporting the identification of a new biochemical pathway to control insulin secretion from islet beta cells in the pancreas, establishing a potential target for insulin control.
Dirty,Crusty Meals Fit for (Long-Dormant) Microbes
Researchers apply the latest analytical techniques to further our understanding of desert biocrusts.
CSI -- On The Metabolite's Trail
Bioinformaticians at the University of Jena make the most efficient search engine for molecular structures available online.
First Complete Structural Study Of A Pegylated Protein
Significant data obtained at NUI Galway reports first crystal structure of a protein modified with a single PEG chain.
Potential Ovarian Cancer Biomarker Isolated
Researchers from North Carolina State University utilized a highly sensitive mass spectrometry analysis to identify and measure difficult-to-detect N-glycan biomarkers associated with ovarian cancers in stages I – IV.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,700+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos